Septerna Inc (SEPN)

Mar 31, 2025, 2:34 PM EDT - 3 days ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS GERN LLY NVO

Mar 27, 2025, 8:00 AM EDT - 7 days ago

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 10:32 AM EDT - 15 days ago

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Mar 6, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out

Mar 5, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Shareholders to Learn More About the Investigation

Mar 4, 2025, 10:00 AM EST - 4 weeks ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 3, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Shareholders to Inquire about Securities Investigation

Mar 2, 2025, 10:00 AM EST - 4 weeks ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 28, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Septerna, Inc. (SEPN) And Encourages Investors to Connect

Feb 27, 2025, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Stockholders to Inquire about Securities Investigation

Feb 26, 2025, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Investors to Learn More About the Investigation

Feb 26, 2025, 8:00 AM EST - 5 weeks ago

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 10:00 AM EST - 5 weeks ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Stockholders to Learn More About the Investigation

Feb 21, 2025, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation

Feb 20, 2025, 10:00 AM EST - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out

Feb 19, 2025, 2:00 PM EST - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out

Feb 18, 2025, 4:15 PM EST - 6 weeks ago

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Feb 18, 2025, 8:00 AM EST - 6 weeks ago

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Dec 18, 2024, 8:00 AM EST - 3 months ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 7:00 AM EST - 4 months ago

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 19, 2024, 2:10 PM EST - 4 months ago

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Oct 30, 2024, 4:41 PM EDT - 5 months ago

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Oct 26, 2024, 1:30 AM EDT - 5 months ago

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

INGM LBGJ PRB ROLR SAG SNYR

Oct 25, 2024, 12:25 PM EDT - 5 months ago

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Oct 24, 2024, 9:47 PM EDT - 5 months ago

Septerna Prices Upsized Initial Public Offering

Oct 24, 2024, 8:11 AM EDT - 5 months ago

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Oct 21, 2024, 6:26 AM EDT - 5 months ago

Biotech Septerna aims to raise up to $186 million in US IPO

Oct 7, 2024, 11:36 AM EDT - 6 months ago

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline